Soluble urokinase-type plasminogen activator receptor in FSGS: stirred but not shaken.
作者信息
Reiser Jochen, Chapman Harold
机构信息
Department of Medicine, Rush University Medical Center, Chicago, Illinois; and
Department of Medicine, University of California, San Francisco, California.
出版信息
J Am Soc Nephrol. 2014 Aug;25(8):1611-3. doi: 10.1681/ASN.2014030257. Epub 2014 May 1.
Abstract
摘要
相似文献
1
Soluble urokinase-type plasminogen activator receptor in FSGS: stirred but not shaken.局灶节段性肾小球硬化中的可溶性尿激酶型纤溶酶原激活物受体：搅动而非震动
J Am Soc Nephrol. 2014 Aug;25(8):1611-3. doi: 10.1681/ASN.2014030257. Epub 2014 May 1.
2
suPAR is the circulating factor in some but not all FSGS.可溶性尿激酶型纤溶酶原激活物受体（suPAR）是部分而非所有局灶节段性肾小球硬化（FSGS）中的循环因子。
Nat Rev Nephrol. 2014 Oct;10(10):610. doi: 10.1038/nrneph.2014.113-c1. Epub 2014 Aug 26.
3
Glomerular disease: The search goes on: suPAR is not the elusive FSGS factor.肾小球疾病：探索仍在继续：可溶性尿激酶型纤溶酶原激活物受体并非难以捉摸的局灶节段性肾小球硬化因子。
Nat Rev Nephrol. 2014 Aug;10(8):431-2. doi: 10.1038/nrneph.2014.113. Epub 2014 Jun 24.
4
Reply: Measurement of serum suPAR is not ready for clinical use.回复：血清可溶性尿激酶型纤溶酶原激活物受体（suPAR）的检测尚未准备好用于临床。
Nat Rev Nephrol. 2014 Oct;10(10):610. doi: 10.1038/nrneph.2014.113-c2. Epub 2014 Aug 26.
5
Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.单独给予重组可溶性尿激酶受体不足以在小鼠中诱导足细胞改变和蛋白尿。
J Am Soc Nephrol. 2014 Aug;25(8):1662-8. doi: 10.1681/ASN.2013040425. Epub 2014 May 1.
6
Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.阿米洛利的脱靶效应抑制足细胞尿激酶受体的表达，减少蛋白尿。
Nephrol Dial Transplant. 2012 May;27(5):1746-55. doi: 10.1093/ndt/gfr612. Epub 2011 Nov 9.
7
1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria.1,25-二羟维生素 D(3) 可抑制足细胞 uPAR 表达，减少蛋白尿。
PLoS One. 2013 May 31;8(5):e64912. doi: 10.1371/journal.pone.0064912. Print 2013.
8
Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress.足细胞损伤：蛋白尿、尿纤溶酶原及氧化应激的作用
Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1308-F1317. doi: 10.1152/ajprenal.00162.2016. Epub 2016 Jun 22.
9
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.采用强化血浆置换及可溶性尿激酶型纤溶酶原激活物受体介导的足细胞β3整合素激活同步监测治疗复发性原发性局灶节段性肾小球硬化症
Transplantation. 2015 Dec;99(12):2593-7. doi: 10.1097/TP.0000000000000914.
10
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.局灶节段性肾小球硬化中的可溶性尿激酶受体：科学观点综述
J Immunol Res. 2016;2016:2068691. doi: 10.1155/2016/2068691. Epub 2016 Jul 18.
引用本文的文献
1
Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association.局灶节段性肾小球硬化中的自身免疫：一种长期存在但难以捉摸的关联。
Front Med (Lausanne). 2020 Nov 20;7:604961. doi: 10.3389/fmed.2020.604961. eCollection 2020.
2
Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.可溶性尿激酶型纤溶酶原激活物受体（suPAR）在局灶节段性肾小球硬化症中的诊断和预后价值及其检测方法的影响。
Sci Rep. 2019 Sep 24;9(1):13783. doi: 10.1038/s41598-019-50405-8.
3
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.采用强化血浆置换及可溶性尿激酶型纤溶酶原激活物受体介导的足细胞β3整合素激活同步监测治疗复发性原发性局灶节段性肾小球硬化症
Transplantation. 2015 Dec;99(12):2593-7. doi: 10.1097/TP.0000000000000914.
4
suPAR is the circulating factor in some but not all FSGS.可溶性尿激酶型纤溶酶原激活物受体（suPAR）是部分而非所有局灶节段性肾小球硬化（FSGS）中的循环因子。
Nat Rev Nephrol. 2014 Oct;10(10):610. doi: 10.1038/nrneph.2014.113-c1. Epub 2014 Aug 26.
5
Ten-year advances in immunopathology of glomerulonephritis: translated into patients' care or lost in translation?肾小球肾炎免疫病理学十年进展：转化为患者护理了吗？还是在翻译中迷失了？
Semin Immunopathol. 2014 Jul;36(4):377-9. doi: 10.1007/s00281-014-0437-5. Epub 2014 Jul 24.
本文引用的文献
1
Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.单独给予重组可溶性尿激酶受体不足以在小鼠中诱导足细胞改变和蛋白尿。
J Am Soc Nephrol. 2014 Aug;25(8):1662-8. doi: 10.1681/ASN.2013040425. Epub 2014 May 1.
2
Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?目前的 ELISA 方法检测血清 suPAR 是否为 FSGS 的可靠诊断生物标志物？
Kidney Int. 2014 Mar;85(3):499-501. doi: 10.1038/ki.2013.549.
3
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.血清可溶性尿激酶受体水平不能区分局灶节段性肾小球硬化与儿童肾病综合征的其他病因。
Kidney Int. 2014 Mar;85(3):649-58. doi: 10.1038/ki.2013.546. Epub 2014 Jan 15.
4
Is there clinical value in measuring suPAR levels in FSGS?测量局灶节段性肾小球硬化症患者的可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平有临床价值吗？
Clin J Am Soc Nephrol. 2013 Aug;8(8):1273-5. doi: 10.2215/CJN.06170613. Epub 2013 Jul 25.
5
Circulating suPAR in two cohorts of primary FSGS.原发性 FSGS 两队列的循环 suPAR。
J Am Soc Nephrol. 2012 Dec;23(12):2051-9. doi: 10.1681/ASN.2012030302. Epub 2012 Nov 8.
6
In vivo electroporation and non-protein based screening assays to identify antibodies against native protein conformations.用于鉴定针对天然蛋白质构象的抗体的体内电穿孔和基于非蛋白质的筛选测定。
Hybridoma (Larchmt). 2011 Oct;30(5):409-18. doi: 10.1089/hyb.2010.0120.
7
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.循环尿激酶受体是局灶节段性肾小球硬化的病因。
Nat Med. 2011 Jul 31;17(8):952-60. doi: 10.1038/nm.2411.
8
PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the alphavbeta5 and alpha5beta1 integrins.纤溶酶原激活物抑制剂1（PAI1）通过αvβ5和α5β1整合素之间的相互作用刺激骨肉瘤细胞中纤连蛋白基质的组装。
J Cell Sci. 2008 May 15;121(Pt 10):1661-70. doi: 10.1242/jcs.020149. Epub 2008 Apr 29.
9
Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.尿激酶受体上玻连蛋白结合位点的定位：由结构域I和侧翼结构域间连接区的残基组成的连贯受体界面的参与。
J Biol Chem. 2007 May 4;282(18):13561-72. doi: 10.1074/jbc.M610184200. Epub 2007 Mar 13.
10
Regulation of integrin function by the urokinase receptor.尿激酶受体对整合素功能的调节
Science. 1996 Sep 13;273(5281):1551-5. doi: 10.1126/science.273.5281.1551.
Zotero 插件